ARWR
What one share of Arrowhead Pharmaceuticals holds
Pharmaceutical Preparations
The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.
Arrowhead Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.79 |
|---|---|
| Profit | −$2.29 |
| Capex (buildings and equipment) | $0.11 |
| Free cash flow | −$0.54 |
| Cash and investments | $0.39 |
| Book value | $3.30 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.34 | $0.06 | −$1.12 | — | $1.37 |
| 2017 | — | −$0.47 | $0.11 | −$0.43 | — | $1.09 |
| 2018 | — | −$0.65 | $0.02 | −$0.58 | — | $1.08 |
| 2019 | — | $0.69 | $0.12 | $1.63 | — | $2.56 |
| 2020 | — | −$0.84 | $0.12 | −$1.07 | — | $4.51 |
| 2021 | — | −$1.36 | $0.23 | $1.42 | — | $3.92 |
| 2022 | — | −$1.67 | $0.50 | −$1.79 | — | $3.76 |
| 2023 | — | −$1.92 | $1.66 | −$3.10 | — | $2.53 |
| 2024 | — | −$5.00 | $1.18 | −$5.05 | — | $1.49 |
| 2025 | $6.20 | −$0.01 | $0.17 | $1.17 | — | $3.43 |